Combination drug therapy for early-stage nasal-type lymphoma
Part of Cancer clinical trials.
This trial tests a combination of three drugs—sintilimab, chidamide, and azacitidine—for people newly diagnosed with a rare type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that is in early stages (I or II). The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been newly diagnosed with extranodal NK/T-cell lymphoma (ENKTL), confirmed by a biopsy.
- Your lymphoma is in an early stage (I or II) and has not spread widely.
- You are generally able to care for yourself (ECOG score 0-2).
- You have at least one tumor that can be measured or seen on scans.
- You do not have active hepatitis B or C, HIV, or other serious health conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This trial tests whether adding the immunotherapy drug sintilimab to a standard chemotherapy regimen (P-GEMOX) works better than chemotherapy alone for people with advanced ENKTL lymphoma. The goal is to see if the combination improves outcomes.
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
This study compares two different combinations of chemotherapy drugs to see which works better for people with early-stage nasal-type or advanced-stage natural killer/T-cell lymphoma. The goal is to find a more effective treatment with manageable side effects.
Hear when a new Progression-Free Survival trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.